We were underpowered to determine whether our GxM findings were responsible for the observed differences in breast cancer TP53 and PIK3CA mutation frequency for individuals of non-European populations and for variants associated with specific PIK3CA mutations (e.g., p.E542K, p.E545K, and p.H1047R/L). This evidence concerns the gene PIK3CA and breast cancer.